| CRISPR Medicine | This is an overview of articles on safety
The small molecule AZD7648 has shown striking potential to enhance HDR in CRISPR editing, raising hopes for clinical translation. But a closer look by...
Irish-Indian company CyGenica is on a mission to solve the huge challenge surrounding targeted intracellular delivery of gene-editing and other...
Resistance to chemotherapy is a major challenge in the treatment of non-small cell lung cancer. By profiling the spectrum of outcomes arising from...
In 2022, we celebrate a decade of CRISPR as a game-changing tool in research and medicine. The last 10 years have been phenomenal, and CRISPR cures...
The FDA recently placed a temporary hold on a clinical trial with TALEN gene-edited CAR T-cells. A patient enrolled in this trial developed...
Just as the summer was creeping in, we hosted our most popular CMN webinar to date. The topic was CRISPR Off-Targets with speakers from academia and a...
Erik Sontheimer, Professor and Vice Chair at the RNA Therapeutics Institute and at the University of Massachusetts Medical School talks to CRISPR...
DECODR's algorithm can quickly — and cheaply — make sense of Sanger sequencing data at a very precise level.
